Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are surging on Monday, up 44% as the company announced strategic updates regarding its clinical trials. The price movement follows news that Sagimet plans to initiate a Phase 3 clinical trial of its acne treatment, denifanstat, in the U.S. in the second half of 2026 Sagimet Biosciences Stock Jumps On Denifanstat Phase 3 Plans Sagimet on Monday highlighted its focus on dermatology, with plans for a Phase 3 clinical trial of denifanstat targeting moderate to severe acne. The company also mentioned ongoing development of its FASN inhibitor, TVB-3567, and a KOL event scheduled for April 30, 2026, to discuss its acne treatment strategy. Concurrently, on Monday, Sagimet Biosciences priced an underwritten offering of 29.17 million shares at $6.00 per share, with gross proceeds expected to be approximately $175.0 million. Sagimet will use the proceeds from the offering, together with its existing cash, cash equivalents, and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, fund TVB-3567 through Phase 2 topline results, advance a topical formulation FASN inhibitor to an IND submission, and for general corporate purposes. The company currently expects that its existing cash and cash equivalents, together with the proceeds from the offering, will fund its acne programs through 2028. Read Also: Also Read: AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug SGMT Technical Outlook: Uptrend And Key Support Levels Sagimet is currently trading within a strong upward trend, positioned 56.2% above its 20-day simple moving average (SMA) and 61.2% above its 50-day SMA, suggesting robust short-term momentum. The stock is also trading 52.6% above its 100-day SMA, indicating a strong intermediate trend. The relative strength index (RSI) is at 53.93, suggesting that the stock is in neutral territory, which indicates balanced buying and selling pressure. This positioning allows room for further upward movement without immediate overbought concerns. Key Resistance: $10.00 — A critical level where upward momentum may stall. Key Support: $8.00 — A level where buying interest may emerge if tested. Sagimet has demonstrated a remarkable 12-month performance of 166.47%, reflecting strong long-term growth and investor interest. Currently, the stock is trading near its 52-week high of $11.41, indicating positive sentiment and potential for continued upward movement. SGMT Price Action: Sagimet Biosciences shares were up 44.03% at $8.44 at the time of publication on Monday, according to Benzinga Pro data. Photo: PeopleImages.com – Yuri A via Shuttestock Read Also: Read Next: Semi Mania; OpenAI May Recruit Qualcomm To Challenge Apple's Smartphone; Two Major Market Triggers Ahead